Bluejay Diagnostics Inc Stock Price, News & Analysis

Bluejay Diagnostics (NASDAQ:BJDX) reported Q3 2025 results and highlighted clinical and financing progress.

Key facts: SYMON-II pivotal trial is ~50% enrolled and aims to validate IL-6 predictive performance for 28-day mortality; Symphony sample testing is planned by late 2026 and a potential FDA 510(k) submission is targeted in 2027, subject to financing. The company completed a $4.5M PIPE in October and a $3.85M warrant-inducement in April; cash was $3.08M and stockholders’ equity $3.69M as of Sept 30, 2025. Bluejay amended supply agreements with SanyoSeiko and says Symphony delivers results in ~20 minutes.

Bluejay Diagnostics (NASDAQ: BJDX) announced on October 10, 2025 the closing of a private placement that generated $4.5 million gross proceeds. The offering comprised 2,250,000 shares of common stock (or pre-funded warrants) and accompanying Series F warrants to purchase up to 4,500,000 shares at a purchase price of $2.00 per share and Series F warrant exercise price of $1.75. Series F warrants are exercisable immediately and expire in five and one-half years. Rodman and Renshaw acted as placement agent. The company said net proceeds will fund FDA approval efforts and related clinical studies, R&D, and general working capital. Securities were sold in a Regulation D/private placement with agreed resale registration rights.

Bluejay Diagnostics (NASDAQ: BJDX) announced a private placement to raise approximately $4.5 million by selling 2,250,000 shares (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares at a $2.00 purchase price and accompanying warrants. The Series F warrants carry a $1.75 exercise price, are exercisable immediately and expire 5.5 years after issuance. The offering is priced at-the-market under Nasdaq rules, is expected to close on or about October 10, 2025, and is being placed exclusively by Rodman and Renshaw. Net proceeds are intended to fund FDA approval efforts (including clinical studies), R&D, and general working capital. Securities will be issued under applicable exemptions and subject to resale registration rights.

Bluejay Diagnostics (NASDAQ: BJDX) and SanyoSeiko agreed on Oct. 9, 2025 to amend their Master Service Agreement and Master Supply Agreement to expand SanyoSeiko’s role in commercializing the Symphony near-patient testing platform.

Under statements of work already provided, SanyoSeiko will provide end-to-end support including manufacturing redevelopment for analyzers and cartridges, hardware/software/design updates, raw material sourcing, vendor compliance, kit assembly, labeling, packaging, shipping, quality control, regulatory and quality management support, and equipment storage and maintenance. The companies say the amended agreements aim to strengthen supply chain resilience, secure production capacity, and advance readiness for broader clinical validation and market introduction.

Bluejay Diagnostics (NASDAQ: BJDX) has reported its Q2 2025 business update, highlighting progress in its Symphony IL-6 test program. The company has initiated the SYMON-II pivotal clinical trial to validate findings from the successful SYMON-I pilot study, with completion expected by end of 2026 and FDA 510(k) submission targeted for 2027.

Key developments include a manufacturing partnership with SanyoSeiko Co. for the Symphony analyzer and an amended agreement with Toray Industries extending cartridge manufacturing timeline to October 2026. The company raised $3.85 million through warrant inducement financing in April 2025 but anticipates requiring additional capital through 2027 for manufacturing, clinical trials, and regulatory activities.

Bluejay Diagnostics (NASDAQ: BJDX) provided a mid-year update highlighting progress in its SYMON clinical program for sepsis detection. The company has initiated the SYMON-II pivotal study following successful SYMON-I pilot results, which showed IL-6 levels' potential to predict sepsis mortality. Bluejay aims for FDA 510(k) submission of its Symphony IL-6 test by Q4 2027, targeting approval by Q3 2028. The company faces financial challenges with $5.7M cash on hand, recent losses of $7.7M in 2024, and needs to raise $30M through 2027. Cost-saving measures include reducing headcount to 5 employees. A reverse stock split is proposed to maintain Nasdaq listing compliance. Manufacturing challenges persist as Bluejay explores outsourcing cartridge redevelopment while maintaining collaboration with SanyoSeiko for analyzer production.

Bluejay Diagnostics (NASDAQ: BJDX) has announced the acceptance of an abstract for presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting in Philadelphia. The presentation will showcase new clinical data from the SYMON-I study, which evaluated the Symphony IL-6 Test in sepsis patients.

The study assessed IL-6 as a prognostic indicator for 28-day mortality, 7-day mortality, and microbiological positivity in patients intended or admitted to intensive care units. Dr. Nathan Shapiro from Beth Israel Deaconess Medical Center highlighted that early IL-6 testing shows promise in predicting short-term and mid-term mortality in sepsis patients.

The company is currently conducting the SYMON-II validation clinical study to further establish IL-6 as a prognostic biomarker. The presentation, titled 'Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study (SYMON I)', will be delivered by Dr. John H. Lee and Dr. Nathan Shapiro on May 14, 2025.

Bluejay Diagnostics (NASDAQ: BJDX) has announced a warrant inducement transaction that will generate approximately $3.7 million in gross proceeds. The agreement involves institutional investors who are existing warrant holders exercising their rights to purchase up to 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share.

In exchange for exercising their existing warrants, investors will receive new warrants to purchase an additional 1,085,106 shares of common stock. These new warrants are immediately exercisable at $3.42 per share and will expire in five years. The transaction was facilitated by Aegis Capital Corp. as the exclusive financial advisor, with legal counsel provided by Hogan Lovells US LLP for Bluejay and Kaufman & Canoles, P.C. for Aegis.

Bluejay Diagnostics (NASDAQ: BJDX) has announced a 1-for-50 reverse stock split effective November 18, 2024. The split will reduce outstanding common stock from approximately 27,624,740 shares to 552,854 shares. Trading will continue under the symbol 'BJDX' with a new CUSIP number 095633509. Stockholders will receive cash payments for fractional shares, and the split will proportionally adjust all outstanding equity awards and warrants. The company's transfer agent, Continental Stock Transfer & Trust Company, will manage the exchange process.